MyndMove
Commercial- Indications
- Stroke, Spinal cord injury
Company intelligence / Profile preview
MyndTec’s flagship product, MyndMove™, is commercially available in the US and Canada for non-invasive neurostimulation to restore arm/hand movement after stroke or spinal cord injury. Clinical studies have shown significant improvements in movement and function, even when other therapies failed. The company is also developing an AI-driven platform, MyndLink™, to optimize chronic pain treatment decisions, and a preclinical regenerative medicine program using patient-derived neural stem cells guided by electrical stimulation
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MyndTec.